Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of Litapiprant in Healthy Subjects
NCT03663686Phase 1Completed
- Sponsor
- Sunshine Lake Pharma
- Start
- Oct 2018
- Primary completion
- Jan 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of litapiprant in asthma (7 cohorts), sponsored by Sunshine Lake Pharma. Primary endpoint: Adverse events. Started Oct 2018; status: completed.
02
Drugs
litapiprant
03
Conditions
asthma
Beyond the preview
Go deeper on NCT03663686.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03663686.